EDAP TMS S.A. American Depositary Shares (FOCL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 47 | 52 | 58 | 65 | 69 | 71 | 69 | 54 |
| Operating profit | $m | -25 | -27 | ||||||
| Net profit | $m | -2 | 1 | -3 | -23 | -21 | -29 | -39 | -37 |
| EPS reported | $ | -0.78 | -1.04 | ||||||
| Operating cashflow per share | $ | -0.44 | -0.38 | ||||||
| Capex per share | $ | 0.13 | 0.13 | ||||||
| FCF per share | $ | -0.57 | -0.52 | ||||||
| Free cash flow | $m | -21 | -18 | ||||||
| Net debt | $m | 5 | 18 | ||||||
| Book value equity | $m | 19 | - | ||||||
| Book value per share | $ | 0.52 | -0.09 | ||||||
| Number of shares | m | 37.44 | 37.53 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.35 | -55.39 | ||||||
| P/S LTM | x | 1.74 | 1.78 | ||||||
| P/FCF LTM | x | -5.76 | -6.97 | ||||||
| EV/EBITDA LTM | x | -5.21 | -4.93 | ||||||
| EV/Sales LTM | x | 1.84 | 3.16 | ||||||
| Earnings Yield LTM | % | -23.82% | -21.77% | ||||||
| FCF Yield | % | -17.37% | -14.36% | ||||||
| Quality | |||||||||
| ROE | % | -151.12% | -289.98% | ||||||
| ROIC | % | -49.23% | -68.72% | ||||||
| Operating margin | % | -35.63% | -39.32% | ||||||
| Gross margin | % | +42.54% | +45.98% | ||||||
| FCF/Sales | % | -30.25% | -28.07% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +2.01% | -0.30% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.77 | -0.44 | ||||||
| Net Debt/EBITDA | x | -0.29 | -1.51 | ||||||
| EBIT/Net interest | x | -31.85 | -4.92 | ||||||
| Net debt/market cap | % | +20.50% | +21.89% | ||||||
| Net debt/Equity | x | 0.25 | - | ||||||
| Gross debt/equity | x | 1.43 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
EDAP TMS S.A. American Depositary Shares (FOCL)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free